HRS-4642
- Generic Name
- HRS-4642
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06938282
HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1
Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06773130
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Metastatic Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 32
- Registration Number
- NCT06770452
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-06
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06587061
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06520488
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 35
- Registration Number
- NCT06427239
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase 1
- Conditions
- Advanced KRAS G12D Mutant Solid Tumors
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06385678
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05533463
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, ShangHai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath